Active Pharmaceutical Ingredients

• Nutraplus India Board approved delayed Q3 FY24 results, reporting a net loss of ₹2.71 lakh with zero revenue from operations. • The company's property, plant, and equipment were auctioned under SARF

Board approved unaudited Q1 June 2024 results showing ₹0.10 lakhs revenue and ₹0.39 lakhs net loss. Auditors issued qualified review citing non-compliance with listing norms and delayed submission due